Saltar al contenido

BioNTech gibt geplanten Ruhestand von Sean Marett bekannt

MAINZ, Deutschland, 7. März, 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech” oder “das Unternehmen”) gab heute bekannt, dass Sean Marett, Chief Business and Commercial Officer, in den Ruhestand gehen und damit wie geplant aus dem Vorstand von BioNTech ausscheiden wird. Ab dem 1. Juli 2024 wird Sean Marett dem Unternehmen mindestens bis Ende des Jahres als Fachberater zur Verfügung stehen. BioNTech wird bis Ende März 2024 die Nachfolge für die Rolle des Chief Commercial Officer bekanntgegeben. Sean Maretts Verantwortlichkeiten als Chief Business Officer werden schrittweise auf Dr. James Ryan, Chief Legal Officer, übertragen, der nach Abschluss der Übergangsphase und nach Sean Maretts Ausscheiden die Rolle des Chief Business Officer von BioNTech übernehmen wird. BioNTech gibt geplanten Ruhestand von Sean Marett bekannt

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments

– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieving all primary and secondary endpoints; initiation of the first Phase 3 clinical trial expected in 2H 2024 – EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments

Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, March 07, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing has begun in Turkey for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver. Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Spectral AI anuncia filial de propiedad intelectual para centrarse en el ecosistema más amplio de IA en el cuidado de la salud

DALLAS, March 07, 2024 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the formation of a wholly-owned subsidiary dedicated to advancing intellectual property (IP) relevant to the broader AI ecosystem, with a specific emphasis on healthcare. Spectral AI Announces Intellectual Property Subsidiary to Focus on the Broader AI Healthcare Ecosystem

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting to be held at the San Diego Convention Center in San Diego, California from April 5–10, 2024.  BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Reviva to Present at the 36th Annual ROTH Conference

CUPERTINO, Calif., March 07, 2024 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the 36th Annual ROTH Conference, taking place March 17-19, 2024, in Dana Point, CA. Reviva to Present at the 36th Annual ROTH Conference

Deutschland kann Asthma-Patienten nicht mehr mit Salbutamol versorgen

Mitte Dezember hat das Bundesgesundheitsministerium (BMG) für Salbutamol-haltige Arzneimittel zur pulmonalen Anwendung einen Versorgungsmangel festgestellt. Das berichtet Apotheke ad hoc. Alternative gleichwertige Therapien stehen dem Bericht zufolge „nicht zur Verfügung“. Die Feststellung des Versorgungsmangels ermögliche einen vereinfachten Import und kann von lebensrettender Bedeutung sein. Salbutamol gehöre „zu den Beta-Sympathomimetika und wird aufgrund seines schnellen Wirkeintritts und bronchienerweiternden Effekts bei einem akuten Asthmaanfall eingesetzt. Der Wirkstoff bindet selektiv an die Beta-2-Adrenozeptoren der Bronchialmuskulatur“. https://www.apotheke-adhoc.de/nachrichten/detail/markt/salbutamol-aus-spanien-und-bronchospray-novo/

Nanosurgical tool could be key to cancer breakthrough

The high-tech double-barrel nanopipette, developed by University of Leeds scientists, and applied to the global medical challenge of cancer, has – for the first time – enabled researchers to see how individual living cancer cells react to treatment and change over time – providing vital understanding that could help doctors develop more effective cancer medication.  The tool has two nanoscopic needles, meaning it can simultaneously inject and extract a sample from the same cell, expanding its potential uses. And the platform’s high level of semi-automation has sped up the process dramatically, enabling scientists to extract data from many more individual cells, with far greater accuracy and efficiency than previously possible, the study shows. Currently, techniques for studying single cells usually destroy them, meaning a cell can be studied either before treatment, or after.  This device can take a “biopsy” of… 

more »Nanosurgical tool could be key to cancer breakthrough

New Center for Synthetic Genomics

Applying and developing new technologies for DNA synthesis to pave the way for producing entire artificial genomes – that is the goal of a new interdisciplinary center that is being established at Heidelberg University, Karlsruhe Institute of Technology (KIT), and Johannes Gutenberg University Mainz (JGU). The aim of the Center for Synthetic Genomics is to spark new developments in synthetic genomics through basic research and technology development using methods of artificial intelligence. The Carl Zeiss Foundation (CZS) is financing the center’s establishment over a period of six years with a total amount of twelve million euros. The Carl Zeiss Foundation Center for Synthetic Genomics Heidelberg – Karlsruhe – Mainz started work in January 2024. Researchers collaborating at the three locations represent different disciplines, including biology, biochemistry, biophysics, biotechnology, synthetic biology, and bioengineering, as well as philosophy and law, genomics, immunology,… 

more »New Center for Synthetic Genomics

Robotergestützte Operationen: Wie KI-basierte Systeme den Chirurgen unterstützen

Einführung in robotergestützte Operationen Die Medizin ist ein Bereich, in dem kontinuierliche Innovationen stattfinden, um Leben zu retten und die Lebensqualität von Patienten zu verbessern. Eine solche Innovation ist die Einführung von robotergestützten Operationen und der Einsatz von künstlicher Intelligenz (KI) zur Unterstützung der Chirurgen. Die Entwicklung der KI in der Chirurgie Anfänge der robotischen […] Robotergestützte Operationen: Wie KI-basierte Systeme den Chirurgen unterstützen